Search

Your search keyword '"Shinichiro Chujo"' showing total 2 results
Start Over Author "Shinichiro Chujo" Publisher mdpi ag
2 results on '"Shinichiro Chujo"'

1. Intraocular Inflammation Secondary to Intravitreal Brolucizumab Injection for Neovascular Age-Related Macular Degeneration in a Patient with Cognitive Impairment

Author

Natsuki Ueji, Yoko Mase, Akiko Kubo, Hisashi Matsubara, Shinichiro Chujo, Yoshitsugu Matsui, and Mineo Kondo

Subjects
age-related macular degeneration, AMD, intraocular inflammation, IOI, brolucizumab, dementia, Medicine (General), R5-920
Abstract

Background and Objectives: Brolucizumab (IVBr) is a recently introduced anti-vascular endothelial growth factor (anti-VEGF) which has been found to be very effective in treating neovascular age-related macular degeneration (nAMD). We reported our findings in a case of nAMD that developed intraocular inflammation (IOI) after IVBr injections. Materials and Methods: A 79-year-old man was referred to our hospital complaining of reduced vision in both eyes of one-month’s duration. His decimal best-corrected visual acuity (BCVA) was 0.9 in the right eye and 1.0 in the left eye. He was diagnosed with nAMD in the left eye and was treated with intravitreal aflibercept (IVA). Despite the three-monthly IVA injections, the serous retinal pigment epithelial detachment (PED) and subretinal fluid (SRF) remained, and the VA gradually decreased to 0.1. Because of the patient being refractory to aflibercept treatment, we switched to 3-monthly IVBr injections. The BCVA gradually improved to 0.3 and optical coherence tomography (OCT) showed an absence of the serous PED and SRF. Three weeks after his third IVBr, he returned to our hospital with a complaint of reduced vision in his left eye that he first noted two weeks earlier. Our examination of the left eye showed signs of IOI mainly in the anterior chamber. The inflammation improved with topical steroids but the treatment of the IOI was delayed for two weeks. The patient was instructed that it was important to begin the treatment as soon as the symptoms of IOI developed. We then performed the Mini-Mental State Examination (MMSE), and his score indicated that he had cognitive impairment. Conclusions: We concluded that before beginning IVBr treatment in nAMD patients, a careful assessment must be made of the cognitive status of the patient.

Published
2023
Full Text
View/download PDF

2. Comparison of 2-Year Outcomes between Intravitreal Ranibizumab and Intravitreal Aflibercept for Diabetic Macular Edema with 'Treat-and-Extend' Regimen—Its Usefulness and Problems

Author

Hisashi Matsubara, Atsushi Ichio, Ryohei Miyata, Masahiko Sugimoto, Shinichiro Chujo, Mineo Kondo, Kumiko Kato, Taku Sasaki, and Yoshitsugu Matsui

Subjects
medicine.medical_specialty, Visual acuity, genetic structures, Diabetic macular edema, lcsh:Medicine, Article, 03 medical and health sciences, 0302 clinical medicine, Ophthalmology, medicine, ranibizumab, treat-and-extend regimen, 030304 developmental biology, Aflibercept, 0303 health sciences, business.industry, aflibercept, lcsh:R, Retrospective cohort study, General Medicine, Diabetic retinopathy, medicine.disease, eye diseases, Regimen, 030221 ophthalmology & optometry, sense organs, Intravitreal ranibizumab, Ranibizumab, medicine.symptom, business, diabetic macular edema, medicine.drug
Abstract

Background: To compare the effectiveness of intravitreal ranibizumab (IVR) and intravitreal aflibercept (IVA) performed with the treat-and-extend (TAE) regimen on eyes with diabetic macular edema (DME). Patients and methods: This is a retrospective study of 125 eyes of 125 treatment-na&iuml, ve DME patients who received anti-VEGF injections at three consecutive monthly intervals as the loading phase. The changes in the best-corrected visual acuity (BCVA), central retinal thickness (CRT), diabetic retinopathy severity scale (DRSS), and total injection numbers were compared between the two anti-VEGF agents. Results: Among 125 eyes, 26 eyes completed the treatment with the TAE regimen for 24 months (20.8%). Thirteen eyes of 13 patients (mean age, 70.9 &plusmn, 6.0 years) received intravitreal injections of 0.5 mg ranibizumab, and 13 eyes of 13 patients (65.9 &plusmn, 8.6 years) received 2 mg aflibercept. No significant differences were detected in the baseline demographics. At 24 months, BCVA was significantly improved in both groups, from 0.31 &plusmn, 0.19 to 0.10 &plusmn, 0.12 logMAR units for IVR and 0.41 &plusmn, 0.19 to 0.16 &plusmn, 0.28 logMAR units for IVA (p = 1.29 &times, 10&minus, 9). CRT was significantly reduced in both groups, 440.9 &plusmn, 69.3 to 307.5 &plusmn, 66.4 &mu, m for IVR and 473.9 &plusmn, 71.5 to 317.8 &plusmn, 71.2 &mu, m for IVA (p = 3.55 &times, 9). No significant differences were detected in the improvements of BCVA, CRT in both groups, and the total injection numbers for 24 months (11.0 &plusmn, 1.2 for the IVA group and 12.0 &plusmn, 1.0 the IVR group). DRSS was significantly improved in both groups (p = 0.0004 for IVR and p = 0.009 for IVA). Conclusion: No significant differences were detected in the improvements of BCVA or CRT and injection numbers between the IVR and IVA groups treated with the TAE regimen. These results indicate that the results of the treatment with both agents with the TAE regimen were equally effective, but only 20.8% of patients completed 24 months of continuous treatment with the TAE regimen. Synopsis: There are no significant differences regarding effectiveness between the IVR and IVA groups treated with the TAE regimen for DME eyes.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results